-+ 0.00%
-+ 0.00%
-+ 0.00%

BioCardia publishes 2026 shareholder letter outlining priorities, strategic opportunities

PUBT·06/18/2026 12:02:48
Listen to the news
BioCardia publishes 2026 shareholder letter outlining priorities, strategic opportunities
  • BioCardia outlined 2026 priorities in a shareholder letter, led by a planned Japan PMDA Shonin submission for CardiAMP Cell Therapy in Q4 2026.
  • Japan launch opportunity framed around about 300,000 ischemic heart failure patients, with initial approval expected to target about 20,000.
  • Letter cited prior Japan reimbursement of USD 124,000 per procedure for chronic ischemic heart failure cell therapies.
  • US focus remains enrollment of the confirmatory CardiAMP HF II trial, which FDA has indicated may support Premarket Approval.
  • Strategy also targets partnering for Helix/Heart3D cardiac delivery platform, with eight early-stage gene or cell therapy discussions cited.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-021041), on June 18, 2026, and is solely responsible for the information contained therein.